

# Jesus Perez-Perez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7101914/publications.pdf>

Version: 2024-02-01

41  
papers

707  
citations

623734

14  
h-index

610901

24  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1024  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 58-64.	2.2	122
2	Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 78-86.	3.9	58
3	Endothelial progenitor cells in acute ischemic stroke. <i>Brain and Behavior</i> , 2013, 3, 649-655.	2.2	42
4	A divergent breakdown of neurocognitive networks in Parkinson's Disease mild cognitive impairment. <i>Human Brain Mapping</i> , 2019, 40, 3233-3242.	3.6	38
5	Structural and metabolic brain correlates of apathy in Huntington's disease. <i>Movement Disorders</i> , 2018, 33, 1151-1159.	3.9	37
6	Striatal hypometabolism in premanifest and manifest Huntington's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2183-2189.	6.4	32
7	Circadian Rhythm, Cognition, and Mood Disorders in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2018, 7, 193-198.	1.9	31
8	White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101965.	2.7	27
9	Circulating Endothelial Progenitor Cells and the Risk of Vascular Events after Ischemic Stroke. <i>PLoS ONE</i> , 2015, 10, e0124895.	2.5	24
10	Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity. <i>Frontiers in Psychiatry</i> , 2018, 9, 465.	2.6	24
11	The impact of bilingualism on brain structure and function in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 92-97.	2.2	22
12	Structural brain correlates of dementia in Huntington's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102415.	2.7	19
13	Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. <i>Drugs and Aging</i> , 2015, 32, 401-407.	2.7	18
14	Specific patterns of brain alterations underlie distinct clinical profiles in Huntington's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101900.	2.7	18
15	An active cognitive lifestyle as a potential neuroprotective factor in Huntington's disease. <i>Neuropsychologia</i> , 2019, 122, 116-124.	1.6	17
16	Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1111-1116.	6.4	15
17	Widespread Increased Diffusivity Reveals Early Cortical Degeneration in Huntington Disease. <i>American Journal of Neuroradiology</i> , 2019, 40, 1464-1468.	2.4	15
18	Utility of the Parkinson's disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington's disease. <i>Journal of Neurology</i> , 2020, 267, 1527-1535.	3.6	13

#	ARTICLE	IF	CITATIONS
19	Structural brain correlates of irritability and aggression in early manifest Huntington's disease. <i>Brain Imaging and Behavior</i> , 2021, 15, 107-113.	2.1	13
20	Impaired face-like object recognition in premanifest Huntington's disease. <i>Cortex</i> , 2020, 123, 162-172.	2.4	12
21	Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes. <i>Journal of Neurology</i> , 2021, 268, 3400-3408.	3.6	12
22	Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters. <i>Clinical Nuclear Medicine</i> , 2019, 44, e1-e5.	1.3	11
23	Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 91-94.	2.2	11
24	Phenomenology and disease progression of chorea-acanthocytosis patients in Spain. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 17-21.	2.2	10
25	Structure and Dynamics of Large-Scale Cognitive Networks in Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 343-353.	3.9	8
26	Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. <i>Human Brain Mapping</i> , 2018, 39, 54-71.	3.6	7
27	"String Hallucinations": Multimodal Tactile and Visual Hallucinations in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 180-183.	1.5	6
28	The Free and Cued Selective Reminding Test in Parkinson's Disease Mild Cognitive Impairment: Discriminative Accuracy and Neural Correlates. <i>Frontiers in Neurology</i> , 2020, 11, 240.	2.4	6
29	Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 2162-2172.	3.9	6
30	Preservation of brain metabolism in recently diagnosed Parkinson's impulse control disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2165-2174.	6.4	5
31	Tipping the scales: how clinical assessment shapes the neural correlates of Parkinson's disease mild cognitive impairment. <i>Brain Imaging and Behavior</i> , 2022, 16, 761-772.	2.1	4
32	Interaction between sex and neurofilament light chain on brain structure and clinical severity in Huntington's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2309-2313.	3.7	4
33	Plasma TDP-43 Reflects Cortical Neurodegeneration and Correlates with Neuropsychiatric Symptoms in Huntington's Disease. <i>Clinical Neuroradiology</i> , 2022, 32, 1077-1085.	1.9	4
34	Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa. <i>Journal of Neurology</i> , 2020, 267, 3400-3410.	3.6	3
35	Cognitive and Affective Empathy in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2021, 10, 323-334.	1.9	3
36	Measuring the functional impact of cognitive impairment in Huntington's disease. <i>Journal of Neurology</i> , 2022, 269, 3541-3549.	3.6	3

#	ARTICLE	IF	CITATIONS
37	Arithmetic Word-Problem Solving as Cognitive Marker of Progression in Pre-Manifest and Manifest Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2021, 10, 1-10.	1.9	2
38	Autoscopic phenomena as an atypical psychiatric presentation of Huntington's disease: A case report including longitudinal clinical and neuroimaging data. <i>Cortex</i> , 2020, 125, 299-306.	2.4	1
39	Rasagiline for the treatment of parkinsonism in Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 340-342.	2.2	0
40	F44...Disentangling apathy subtypes in huntington's disease: a white matter biomarker of disease profile and progression. , 2018, , .		0
41	E08...Tracking the neurodegeneration pattern of the anterior thalamic radiations in HD: a focus on brain iron, white matter integrity and metabolites. , 2021, , .		0